Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom-Reference-Cited by-同舟云学术

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

Published:2017-06-21 Issue:6 Volume:12 Page:e0175920
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Amdahl Jordan,Diaz Jose,Sharma Arati,Park Jinhee,Chandiwana David,Delea Thomas E.^ORCID

Funder

Novartis Pharmaceuticals Corporation

GlaxoSmithKline

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference33 articles.

1. Renal-cell carcinoma;HT Cohen;N Engl J Med,2005

2. Egton Medical Information Systems Limited. Renal cancer. 2016. Available: http://patient.info/doctor/renal-cancer. Accessed 22 December 2016.

3. Cancer Research UK. Kidney cancer statistics. Available: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer#heading-Zero. Accessed 5 January 2017.

4. Immunotherapy for advanced renal cell cancer;C Coppin;Cochrane Database Syst Rev,2005

5. Systemic therapy for renal cell carcinoma;RJ Motzer;J Urol,2000

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08

3. Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease Model;Clinical Genitourinary Cancer;2023-08

4. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India;JCO Global Oncology;2023-02

5. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group;Clinical Genitourinary Cancer;2022-08